Retatrutide is not FDA approved. Lilly plans to file in the first quarter of 2027 and is suing sellers of unapproved versions. The latest status.
Written by the Peptide Labs Research Team
No. Retatrutide is an investigational drug from Eli Lilly and the FDA has not approved it. CBS News reported on 28 October 2026 that it has not been reviewed by the FDA and remains in clinical trials.
Manufacturing Chemist reported on 24 July 2026 that Lilly "now plans to submit a Biologics License Application (BLA) to the FDA in the first quarter of 2027". Lilly is still finishing the manufacturing and quality data that application needs, which pushed the filing later than it first indicated. Its third-quarter results on 29 October gave no new date.
No date exists. A filing only starts the FDA's review, so any US launch would come after early 2027 and would depend on approval. A US decision would not apply here either. Australia's Therapeutic Goods Administration makes its own assessment.
The 29 October results listed topline results from a Phase 3 trial comparing retatrutide with semaglutide in adults with type 2 diabetes. Topline means a company summary, before full publication.
Yes. MLex reported four suits filed on 8 October 2026, against an Arizona weight loss clinic and three online sellers. A Frier Levitt article counts "at least 11 federal lawsuits". These are allegations. Our report on the August lawsuits has the background.
Peptide Labs supplies research peptides strictly for in-vitro laboratory use, not for human or animal use. This article reports public news and gives no use or dosing guidance.
The FDA sent five warning letters to online peptide sellers on 24 August 2026. Why research use labels failed and what it said about BAC water.
Industry & RegulationParadigm Peptides owner Matthew Kawa got 70 months in a US prison. Forged lab certificates and research use labels sat at the centre of the case.
99%+ HPLC purity · COA verified every batch · Next-day dispatch to Melbourne
Shop All Peptides